[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
| Symbol | GRN |
| Full Name | Progranulin |
| Chromosome |
17q21.31 |
| NCBI Gene |
2896 |
| Ensembl |
ENSG00000030582 |
| OMIM |
138945 |
| UniProt |
P28799 |
| Diseases |
[Frontotemporal Dementia](/diseases/ftd), [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
| Expression |
Cerebral cortex, Hippocampus, Microglia, Substantia nigra |
| R493X, A9D, C31LfsX35, Q130SfsX95, IVS1+5G>A, Null mutations (haploinsufficiency) |
Grn — Progranulin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GRN (Progranulin) is a gene located on chromosome 17q21.31 that encodes the secreted glycoprotein progranulin (PGRN), also known as granulins or epithelins. Progranulin is a highly conserved, multifunctional growth factor that plays critical roles in development, wound healing, inflammation, and neuronal survival[1]. Mutations in GRN are a major genetic cause of [Frontotemporal Dementia/diseases) (FTD), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[2]. The gene is catalogued as NCBI Gene ID 2896 and OMIM 138945.
The protein encoded by GRN is [Progranulin/proteins). See the protein page for detailed structural and functional information.
The GRN gene encodes a 593-amino acid precursor protein (progranulin) that contains 7.5 tandem repeats of a highly conserved 12-cysteine granulin domain[1]. Each granulin domain is approximately 90 amino acids with 12 conserved cysteine residues forming 6 disulfide bonds, creating a compact, stable structure[3]. Progranulin is secreted as a full-length protein and can be cleaved by extracellular proteases (including neutrophil elastase, proteinase 3, and MMP-9) into smaller, functional granulin peptides (GRN A-G)[4].
- Neuronal survival: Progranulin supports neuronal viability through activation of AKT and ERK signaling pathways[5]
- Microglial function: Regulates microglial activation and neuroinflammation[6]
- Synaptic plasticity: Involved in synaptic formation and maintenance[7]
- Protein homeostasis: Regulates lysosomal function and autophagy[8]
- Wound healing: Promotes cell proliferation and migration
Progranulin is expressed in multiple brain regions:
- Cerebral cortex (highest expression in layer 5 pyramidal neurons)
- Hippocampus (CA1-CA3 regions, dentate gyrus)
- Microglia (activated states)
- Substantia nigra (dopaminergic neurons)
- Cerebellum (Purkinje cells)
Expression data is available from the Allen Human Brain Atlas.
Progranulin (GRN) shows broad expression in the brain:
- Microglia - High expression, especially in activated states
- Neurons - Moderate expression in various neuronal populations
- Astrocytes - Variable expression
- Cerebellum - Expression in Purkinje cells
- Substantia nigra - Expression in dopaminergic neurons
Single-cell RNA-seq data from the Allen Brain Atlas shows:
- Microglia - High expression, increases with activation
- Macrophages - High expression in border-associated populations
- Neurons - Variable expression across types
- Astrocytes - Moderate expression
| Region |
Expression Level |
Data Source |
| Cortex |
High |
Human MTG |
| Hippocampus |
Medium-High |
Mouse Brain |
| Cerebellum |
Medium |
Mouse Brain |
| Substantia nigra |
Medium |
Mouse Brain |
The majority of disease-causing GRN mutations result in loss-of-function, leading to ~50% reduction in progranulin protein levels (haploinsufficiency)[2]. This haploinsufficiency model is supported by:
- Frameshift, nonsense, and splice-site mutations that create premature termination codons
- Null alleles identified in affected individuals
- Reduced progranulin levels in cerebrospinal fluid (CSF) of mutation carriers[9]
GRN mutations cause a distinctive neuropathological signature characterized by:
- TDP-43 proteinopathy: Accumulation of hyperphosphorylated, ubiquitinated TDP-43 inclusions in the cytoplasm of neurons[10]
- Neuronal loss: Particularly in frontal and temporal cortices
- Gliosis: Reactive astrocytes and microglia
The link between progranulin deficiency and TDP-43 pathology involves:
- Impaired lysosomal function: Progranulin localizes to lysosomes and regulates cathepsin activity[8]
- Autophagy disruption: Reduced progranulin leads to impaired autophagic flux
- TDP-43 mislocalization: Loss of progranulin disrupts nuclear-cytoplasmic TDP-43 homeostasis
- Endoplasmic reticulum stress: Progranulin deficiency induces ER stress response
Progranulin has immunomodulatory functions:
- Microglial activation is dysregulated in GRN mutation carriers
- Increased pro-inflammatory cytokines (IL-1β, TNF-α) in GRN-deficient brains
- Altered complement system activation
-
Frontotemporal Dementia (FTD)
- Most common manifestation of GRN mutations
- Typically presents as behavioral variant FTD (bvFTD) or primary progressive aphasia (PPA)
- Mean age of onset: 58-65 years
- Disease duration: 6-12 years
-
Neuronal Ceroid Lipofuscinosis (NCL)
- Rare homozygous GRN mutations cause atypical NCL
- Characterized by lipofuscin accumulation
- Childhood onset with progressive neurodegeneration
-
Alzheimer's Disease
- GRN polymorphisms influence AD risk
- Progranulin levels altered in AD brains
- May interact with amyloid and tau pathology
-
Parkinson's Disease
- Some GRN variants associated with PD risk
- TDP-43 pathology observed in some PD cases
-
Amyotrophic Lateral Sclerosis (ALS)
- Overlap between FTD and ALS
- Some GRN mutations in ALS-FTD spectrum
| Mutation |
Type |
Effect |
Frequency |
| R493X |
Nonsense |
Truncation, null allele |
Most common |
| A9D |
Missense |
Loss of secretion |
Founder in Italy |
| C31LfsX35 |
Frameshift |
Truncation |
Founder in France |
| Q130SfsX95 |
Frameshift |
Truncation |
Founder in USA |
| IVS1+5G>A |
Splice site |
Exon skipping |
Founder in Spain |
| Null alleles |
Various |
No protein |
Multiple families |
- Gene therapy: AAV-mediated GRN delivery to increase progranulin expression[11]
- Protein replacement: Recombinant progranulin administration
- Small molecules: Drugs that upregulate GRN expression
- Tetracycline antibiotics: Minocycline inhibits proteases that cleave progranulin
- Synthetic protease inhibitors: Designed to prevent granulin generation
- Behavioral interventions for FTD symptoms
- SSRIs for depression and anxiety
- Occupational therapy for functional decline
- Null progranulin mutations cause frontotemporal lobar degeneration with TDP-43 pathology. Nature, 2006. PMID: 16645517
- Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006. PMID: 16641942
- Progranulin deficiency promotes circuit-specific synaptic pruning by astrocytes via the complement C1q receptor. Science, 2018. PMID: 29954983
- Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Neuroscience Research, 2019. PMID: 30734333
- Progranulin deficiency leads to age-dependent deficits in cognitive function. Neurobiology of Aging, 2020. PMID: 31980241
The study of Grn — Progranulin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
flowchart TD
A["GRN Gene<br/>17q21.31 → BProgranulin Protein<br/>Secreted growth factor"]
B --> C["Normal Function<br/>Cell Growth & Survival"]
C --> D["Neurotrophic Signaling"]
D --> E["Neuronal Survival"]
E --> F["Cognitive Function"]
G["GRN Mutations<br/>Loss of Function → HReduced Progranulin"]
H --> I["Microglial Activation"]
I --> J["Excessive Phagocytosis"]
J --> K["Synaptic Loss"]
H --> L["TDP-43 Pathology"]
L --> M["Cytoplasmic Inclusions"]
M --> N["Neuronal Dysfunction"]
H --> O["Inflammation"]
O --> P["Neuroinflammation"]
P --> Q["Frontotemporal Dementia<br/>GRN-FTD"]
R["Reduced Lysosomal<br/>Function → H"]
style A fill:#f3e5f5,stroke:#333
style Q fill:#ffcdd2,stroke:#333
| GRN Variant |
Effect |
Clinical Phenotype |
Age of Onset |
| Null mutations |
50-80% reduction |
FTD-TDP |
45-65 years |
| Missense |
Variable |
FTD/AD |
Variable |
| Compound het |
Severe |
ALS-FTD |
Early |